- Alimera and pSivida are partners on ILUVIEN. 16 articles have been published focusing on pSivida since June. Only 1 has focused on Alimera, resulting in a brief Alimera discount.
- In order to fully grasp the potential of ILUVIEN in terms of ROI, knowledge of both companies is essential.
- Alimera gets 80% of ILUVIEN revenues, pSivida 20%. Alimera is trialing ILUVIEN for macular degeneration and retinal vein occlusion, while pSivida is developing fourth-generation insert Tethadur.
- Alimera is a more leveraged play on ILUVIEN specifically, while pSivida is a more varied play on ocular implant technology in general.